All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 [cited 2020 Mar 2]. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf

10.1111/1469-0691.12363

10.1128/AAC.01222-13

10.1093/ofid/ofx176

10.1007/s40121-021-00408-8

10.1086/652237

10.1093/cid/cis688

10.1093/cid/ciz089

10.1016/S0140-6736(12)60964-7

10.3390/molecules24050892

10.1093/cid/ciz829

10.1093/cid/ciz830

10.1128/AAC.01989-17

10.1056/NEJMoa1801467

10.1001/jama.2018.0438

10.1093/jac/dkx139

10.1128/AAC.00633-16

10.1093/cid/ciaa803

10.1016/S1473-3099(18)30554-1

10.1016/S1473-3099(20)30731-3

10.1016/j.jhin.2018.11.018

10.1186/s13054-016-1197-5

10.1517/14656566.2013.821109

FDA. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. Guidance for Industry. 2017. [cited 2021 Apr 14]. Available from: https://www.fda.gov/files/drugs/published/Antibacterial-Therapies-for-Patients-With-an-Unmet-Medical-Need-for-the-Treatment-of-Serious-Bacterial-Diseases.pdf

EMA. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Rev. 3. 2018 [cited 2021 Nov 12]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf

10.2147/IDR.S225553

10.1016/j.cmi.2019.05.004

10.1007/s40121-018-0215-0

10.1056/NEJMc1807634

10.1007/s40121-018-0214-1

10.1016/S1473-3099(20)30796-9

10.1016/S1473-3099(18)30099-9

10.1093/cid/cit253

10.1128/AAC.02435-13

10.1016/j.ijid.2015.07.024

10.1093/cid/ciz530

10.1093/cid/ciaa457

10.1186/s12879-021-06253-x

10.1111/j.1469-0691.2011.03570.x

10.1038/s41598-019-51711-x

10.1093/ofid/ofaa439.475

10.1038/srep17091

10.1186/s12879-020-05026-2

10.1016/j.cmi.2018.01.015

Paterson DL, 2020, Curr Opin Infect Dis, 33, 214, 10.1097/QCO.0000000000000627

10.1128/JCM.03264-15

10.1016/j.jgar.2021.02.004

10.1038/s41579-019-0288-0

Pew Charitable Trust. Tracking the global pipeline of antibiotics in development. March 2021 [cited 2021 Jul 14]. Available from: https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/tracking-the-global-pipeline-of-antibiotics-in-development

Clinicaltrials.gov. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused byAcinetobacter baumannii-calcoaceticuscomplex (ATTACK). [cited 2021 Jul 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03894046

Clinicaltrials.gov. Efficacy, safety, and tolerability of ATM-AVI in the treatment of serious infection due to MBL-producing Gram-negative bacteria. [cited 2021 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03580044

10.1093/cid/cix246

10.1007/s00134-017-4802-4

Farkas J. PulmCrit – chasing mortality endpoints is a fool’s errand. 2018; March 12. [cited 2021 Apr 14]. Available from: https://emcrit.org/pulmcrit/mortality

10.1093/cid/civ495

10.1093/cid/ciz093

ECRAID. European clinical research alliance on infectious diseases. [cited 2021 Jul 14]. Available from: https://www.ecraid.eu

COMBACTE. Combatting bacterial resistance in Europe. [cited 2021 Jul 14]. Available from: https://www.combacte.com

10.1080/14656566.2020.1840552

10.1016/S1473-3099(19)30284-1